Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 In Vitro Diagnostics Diagnostics

Qiagen Ready To Rival Abbott With Rapid, Portable Antigen COVID-19 Test

Executive Summary

The diagnostics company said the test is scheduled for US launch in Q4 2020.

You may also be interested in...



FDA Grants EUA For Access Bio’s Lateral Flow COVID-19 Antigen Test

Access Bio joins Abbott as the second company with FDA authorization to distribute PCR, antigen and antibody tests for COVID-19.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

FDA Authorizes Abbott’s '$5, 15 Minute' COVID-19 Antigen Test

The BinaxNOW COVID-19 Ag Card portable lateral flow test, which delivers rapid results with no instrumentation, could be a “game changer” in the effort to reopen schools and other crowded places.

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Coronavirus COVID-19 In Vitro Diagnostics Diagnostics
Latest Headlines

News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared

AdvaMed Offers Plan To Strengthen Medtech Supply Chain

Warning Letters And Close-Outs – May 2023

Global Medtech Guidance Tracker: May 2023

See All
UsernamePublicRestriction

Register

MT142709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By